Julia Sjöberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Sjöberg has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Valgardur Sigurdsson
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications- Anna Rydström
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
1 shared publication - Els Mansell
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
1 shared publication - Gunnar Keppler Gouras
Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden
1 shared publication Haruki Shirozu
International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan
1 shared publication- Jenny Hansson
Division of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden
1 shared publication
Latest Publications
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7339-7351
Chemotherapy-related anemia is regulated through caspase-1–mediated ROCK1 activation
Hematopoietic stem cells (HSCs) have the ability to produce all cells in the blood system and are crucial for blood and immune recovery after chemotherapy. Patients with cancer often experience anemia, especially during chemotherapy treatment. Severe anemia may cause treatment disruption and is closely linked to a worse prognosis for the patient. We followed hematopoietic recovery in mice after chemotherapy treatment with 5-fluorouracil (5-FU) and found that erythrocyte recovery is delayed compared to other blood lineages. The delayed erythroid recovery manifests itself in HSCs that are transcriptionally and functionally biased toward myeloid cell production at the expense of erythropoiesis. We show that this erythroid deficiency is rescued in a caspase-1−/− mouse model, and that caspase-1 regulates lineage bias through an interleukin-1β–independent mechanism involving rho-associated coiled-coil–containing protein kinase 1 (ROCK1). Inhibiting the caspase-1 substrate ROCK1 leads to a rescue of erythropoiesis after 5-FU treatment. Indeed, we confirmed that ROCK1 is cleaved and activated by caspase-1 upon 5-FU treatment, suppressing erythropoiesis. Currently, patients with cancer who are anemic have limited treatment options for improving their red blood cell numbers. Several ROCK1 inhibitors have already been approved for use in other conditions and could potentially be used to mitigate anemia associated with cancer and chemotherapy, thereby improving quality of life and outcomes for patients with cancer.
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7339-7351
Chemotherapy-related anemia is regulated through caspase-1–mediated ROCK1 activation
Hematopoietic stem cells (HSCs) have the ability to produce all cells in the blood system and are crucial for blood and immune recovery after chemotherapy. Patients with cancer often experience anemia, especially during chemotherapy treatment. Severe anemia may cause treatment disruption and is closely linked to a worse prognosis for the patient. We followed hematopoietic recovery in mice after chemotherapy treatment with 5-fluorouracil (5-FU) and found that erythrocyte recovery is delayed compared to other blood lineages. The delayed erythroid recovery manifests itself in HSCs that are transcriptionally and functionally biased toward myeloid cell production at the expense of erythropoiesis. We show that this erythroid deficiency is rescued in a caspase-1−/− mouse model, and that caspase-1 regulates lineage bias through an interleukin-1β–independent mechanism involving rho-associated coiled-coil–containing protein kinase 1 (ROCK1). Inhibiting the caspase-1 substrate ROCK1 leads to a rescue of erythropoiesis after 5-FU treatment. Indeed, we confirmed that ROCK1 is cleaved and activated by caspase-1 upon 5-FU treatment, suppressing erythropoiesis. Currently, patients with cancer who are anemic have limited treatment options for improving their red blood cell numbers. Several ROCK1 inhibitors have already been approved for use in other conditions and could potentially be used to mitigate anemia associated with cancer and chemotherapy, thereby improving quality of life and outcomes for patients with cancer.
- Open Access
- 16 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 8131
Lipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions
Hematopoietic stem cells (HSCs) react to various stress conditions. However, it is unclear whether and how HSCs respond to severe anemia. Here, we demonstrate that upon induction of acute anemia, HSCs rapidly proliferate and enhance their erythroid differentiation potential. In severe anemia, lipoprotein profiles largely change and the concentration of ApoE increases. In HSCs, transcription levels of lipid metabolism-related genes, such as very low-density lipoprotein receptor (Vldlr), are upregulated. Stimulation of HSCs with ApoE enhances their erythroid potential, whereas HSCs in Apoe knockout mice do not respond to anemia induction. VldlrhighHSCs show higher erythroid potential, which is enhanced after acute anemia induction. VldlrhighHSCs are epigenetically distinct because of their low chromatin accessibility, and more chromatin regions are closed upon acute anemia induction. Chromatin regions closed upon acute anemia induction are mainly binding sites of Erg. Inhibition of Erg enhanced the erythroid differentiation potential of HSCs. Our findings indicate that lipoprotein metabolism plays an important role in HSC regulation under severe anemic conditions.
- 16 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 8131
Open AccessLipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions
Hematopoietic stem cells (HSCs) react to various stress conditions. However, it is unclear whether and how HSCs respond to severe anemia. Here, we demonstrate that upon induction of acute anemia, HSCs rapidly proliferate and enhance their erythroid differentiation potential. In severe anemia, lipoprotein profiles largely change and the concentration of ApoE increases. In HSCs, transcription levels of lipid metabolism-related genes, such as very low-density lipoprotein receptor (Vldlr), are upregulated. Stimulation of HSCs with ApoE enhances their erythroid potential, whereas HSCs in Apoe knockout mice do not respond to anemia induction. VldlrhighHSCs show higher erythroid potential, which is enhanced after acute anemia induction. VldlrhighHSCs are epigenetically distinct because of their low chromatin accessibility, and more chromatin regions are closed upon acute anemia induction. Chromatin regions closed upon acute anemia induction are mainly binding sites of Erg. Inhibition of Erg enhanced the erythroid differentiation potential of HSCs. Our findings indicate that lipoprotein metabolism plays an important role in HSC regulation under severe anemic conditions.